BHARE Foundation

Fall, 2018

Thank you for helping us honor our commitment to donate $128,000 to The Microbiota Transfer Therapy (MTT) research at Arizona State University.   The study is underway and publishing the results may take 2 years or longer.  While patience is required for the completion of this study, we now must be open to looking at other research ideas.

Our focus has shifted to the work of Dr. Robert Naviaux.  He believes people with autism are trapped in a type of “fight or flight” phase.  In 2017 he published a small study that treated 5 subjects with a medication called Suramin.  This drug signals the body to switch to a “rest and digest” phase, which promotes healing, growth, and normal neurodevelopment. All 5 children in the study displayed improvements in language, social interaction, and a decrease in restrictive or repetitive behaviors.   His written proposal to The BHARE Foundation is for $75,000.  Dr. Naviaux is asking us to fund the measuring of metabolomics.  Measuring the metabolomics will tell us exactly what changed in each subject, and help researchers understand why the treatment works on some subjects, but not others.

Dr. Naviaux’s team is ready to begin phase II of the study which will contain a larger group of subjects.   His theory is unique and one that needs to be explored.  According to Dr. Naviaux, “Metabolism is the language that the brain, gut and immune system use to communicate.  These systems are linked. You can’t change one without changing the others.”  To view the first study and other publications regarding this work, go to bhare.org.

We recently received a proposal from Dr. Theoharides from Tufts University, requesting $100,000 for his research on exosomes, also known as extracellular vesicles (EVs).  EVs have been recently implicated in neuropsychiatric diseases.  Dr. Theoharides preliminary work indicates that EV associated protein is elevated in children with autism.  He believes it may be possible that the increased levels of EVs may cause inflammation of the brain.  If he can show that levels of EVs correlate to the severity of autistic symptoms, then EVs could become an important marker for autism.  Furthermore, if he can prove that EVs relate to one’s severity of autism, then this theory might identify a new mechanism for the pathogenesis of ASD.  The presence of EVs could be used for diagnosis, prognosis, and treatment. Future studies could include whether a natural flavonoid called methoxyluteolin could inhibit the EVs from causing brain inflammation.

There is more to accomplish and without funds, the work will simply not get done.   Our donations to Dr. Adams the past 10 years is partially the reason that has enabled him to prove to the government that his work is safe and effective.  That proof enabled him to request and receive almost one million dollars in federal funding.  Our seed money is vital to help get these studies off the ground.  Please send a check or donate via PayPal and ask your employer if they have a matching grant program.  We are focused on finding the underlying causes of autism, which will help us discover new treatments.  Your help will make a difference and is greatly appreciated.

Thank you,

Bram Hornstein
The BHARE Foundation


First Steps Toward a Real Treatment for Autism.

Published in January 2017

The BHARE Foundation is pleased to note that they provided funding for basic scientific research to Profs. Adams and Krajmalnik-Brown, and that basic research provided critical data that helped justify the need for FMT and helped win FDA approval for the clinical trial.

Read the full study here: http://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-016-0225-7

 


Folinic Acid Study

With your support, BHARE has been able to fund another positive study that was published this year. Please take a look at the tremendous effect you are creating by helping us fund research.

Folinic Acid Study